Mannin Research
Mannin Research Inc. is a privately-held, Toronto-based biotechnology company developing first-in-class therapeutics targeting the Ang-Tie2 mechanism of action to treat ophthalmic diseases, with its lead indication being glaucoma.
- Company typePrivate
- Founded2016
- HeadquartersToronto, Canada
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mannin Research does
Mannin Research Inc. is a privately-held Canadian biotechnology company founded in 2016 and headquartered at 80 Atlantic Avenue, Toronto, Ontario. The company is focused on developing and commercializing novel therapeutics for ophthalmic diseases, with its first clinical indication being glaucoma. Mannin pursues a first-in-class drug development strategy centered on therapeutics that engage the Ang-Tie2 signaling pathway—a mechanism implicated in vascular endothelial function and ocular homeostasis.
The company's product portfolio consists of novel drug candidates designed to modulate the Ang-Tie2 mechanism of action to address unmet medical needs in ophthalmology, beginning with glaucoma. Mannin is operating at a very early stage with a team of 1-10 employees, no commercial products, no disclosed partnerships, and no named customers or licensing relationships in the available data. The company's value proposition rests on differentiated biology—the first-in-class positioning of Ang-Tie2 engagement for ocular disease—and its prioritized focus on glaucoma, a large indication with significant unmet need despite existing therapeutic options.
Mannin Research operates as a pre-commercial biotech. No pricing model, distribution channels, marketing channels, or revenue mechanics are in place, and no commercial milestones have been disclosed. The company has raised approximately $3.38 million in funding from Q BioMed as lead investor in November 2022. Future commercialization will likely depend on out-licensing, strategic partnerships, or direct commercialization of approved ophthalmic drugs following clinical and regulatory milestones, none of which have been publicly disclosed to date.
Mannin Research firmographics
Firmographics- Name
- Mannin Research
- Legal name
- Mannin Research Inc.
- Website
- https://mannin.ca
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Mannin Research Inc. is a privately-held, Toronto-based biotechnology company developing first-in-class therapeutics targeting the Ang-Tie2 mechanism of action to treat ophthalmic diseases, with its lead indication being glaucoma.
- Ownership category
- akta.pro rank
Mannin Research industry classification
Industry- Product category
- Ophthalmic Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
- akta.pro secondary industries
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Ophthalmology Pharmaceuticals (HLAIAAAL)
Keywords
Where Mannin Research is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Mannin Research business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Mannin Research product offering
Product offeringCore offering
Mannin Research develops and commercializes novel therapeutics targeting the Ang-Tie2 mechanism of action for ophthalmic diseases. The company's first indication is glaucoma, treated with novel, first-in-class drugs. The company is a pre-commercial biotechnology company focused on the discovery and development of these innovative new drugs to address unmet needs in ophthalmology.
Product overview
Mannin Research is a biotechnology company developing a single portfolio of novel therapeutics targeting the Ang-Tie2 mechanism of action for ophthalmic diseases. The company's lead indication is glaucoma, with drugs classified as first-in-class treatments. Mannin is focused on both developing and commercializing these innovative new drugs to address patient needs in ophthalmology.
Differentiator
Problem solved
Functional benefit
Products and services
- Novel Ang-Tie2 Therapeutics (Glaucoma Program)
Companies that use Mannin Research
Customer profileSegments1 record
Ideal customer profiles1 record
Mannin Research technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Mannin Research partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
Mannin Research competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
Mannin Research social profiles
Digital presenceMannin Research financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mannin Research leadership team
Management profileNumber of profiles
Mannin Research funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mannin Research M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mannin Research
What does Mannin Research do?
Mannin Research develops and commercializes novel therapeutics targeting the Ang-Tie2 mechanism of action for ophthalmic diseases. The company's first indication is glaucoma, treated with novel, first-in-class drugs. The company is a pre-commercial biotechnology company focused on the discovery and development of these innovative new drugs to address unmet needs in ophthalmology.
Is Mannin Research a public or private company?
Mannin Research is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mannin Research founded?
Mannin Research was founded in 2016. It employs 1 to 10 people.
Where is Mannin Research based?
Mannin Research is headquartered in Toronto, Canada, in the North America region.
Does Mannin Research have an API?
No public API is recorded for Mannin Research.
What industry is Mannin Research in?
Mannin Research's product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 325412 and its SIC code is 2834.